Severe Hypertriglyceridemia (SHTG) Treatment Market Snapshot
The global severe hypertriglyceridemia (SHTG) treatment market garnered a market value of US$ 615 Million in 2022 and is expected to accumulate a market value of US$ 2675.37 Million by registering a CAGR of 14.3% in the forecast period 2023-2033. Growth of the severe hypertriglyceridemia (SHTG) treatment market can be attributed to increasing prevalence of SHTG along with technological advancements for manufacturing medications for the ailment. The market for severe hypertriglyceridemia (SHTG) treatment registered a CAGR of 8% in the historical period 2018 to 2022
Severe Hypertriglyceridemia (SHTG) is a medical condition characterized by abnormally high levels of triglycerides in the blood, which can lead to the development of cardiovascular diseases. SHTG is a serious condition that requires prompt treatment to reduce the risk of cardiovascular events such as heart attacks and strokes.
Severe Hypertriglyceridemia (SHTG) Treatment Market refers to the market for pharmaceutical drugs, medical devices, and other products used in the treatment of Severe Hypertriglyceridemia (SHTG).
Report Attribute
Details
Expected Market Value (2023)
US$ 702.95 Million
Anticipated Forecast Value (2033)
US$ 2675.37 Million
Projected Growth Rate (2023 to 2033)
14.3% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Severe Hypertriglyceridemia (SHTG) Treatment Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Severe hypertriglyceridemia (SHTG) treatment reflected a value of 14.3% during the historical period, 2018 to 2022.
The market for SHTG treatment has been growing steadily over the past few years due to the increasing prevalence of SHTG and the growing awareness of the condition. The market growth is driven by various factors, including the increasing prevalence of SHTG, the rise in geriatric population, technological advancements in the field of SHTG treatment, and the growing awareness among patients and healthcare professionals about the risks associated with untreated SHTG.
Thus, the market for Severe hypertriglyceridemia (SHTG) treatment is expected to register a CAGR of 8% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of Severe Hypertriglyceridemia (SHTG) Treatment Market?
Increasing prevalence of severe hypertriglyceridemia and technological advancements driving the growth of SHTG treatment market
The global prevalence of SHTG is increasing, with an estimated 40 million people affected worldwide. This increasing prevalence is a major driver of the SHTG treatment market. With the aging of the global population, there is an increasing prevalence of SHTG among the elderly population. This has created a growing demand for SHTG treatment and is driving the growth of the market.
There have been significant technological advancements in the field of SHTG treatment, including the development of new drugs and medical devices, which are driving the growth of the market. There is a growing awareness among patients and healthcare professionals about the risks associated with untreated SHTG. This is leading to earlier diagnosis and treatment, which is driving the growth of the market.
Governments in many countries are taking initiatives to promote awareness about SHTG and to provide better access to SHTG treatment. This is creating a favorable environment for the growth of the market. As healthcare expenditure continues to increase worldwide, more resources are being allocated to the treatment of chronic conditions such as SHTG. This is driving the growth of the market as well.
Availability of treatments bolstering the market for severe hypertriglyceridemia treatment market
Pharmacological Treatments: Several classes of drugs are used to treat SHTG, including fibrates, omega-3 fatty acid supplements, statins, niacin, and bile acid sequestrants. These drugs work by reducing the levels of triglycerides in the blood.
Medical Devices: Apheresis machines are used in severe cases of SHTG to filter out excess triglycerides from the blood.
Surgery: In very rare cases, surgery may be recommended to treat SHTG, such as in cases where the condition is caused by an underlying genetic disorder.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Faced by the Severe Hypertriglyceridemia (SHTG) Treatment Market?
Limited awareness and high cost of treatment derailing progress of SHTG market
Despite growing awareness about SHTG, many people remain unaware of the condition, which can hinder diagnosis and treatment. The cost of SHTG treatment can be high, particularly for newer drugs and medical devices. This can limit access to treatment for some patients.
Some drugs used to treat SHTG can have side effects, including gastrointestinal problems, liver problems, and muscle pain. This can lead to treatment discontinuation and reduced patient adherence. There are alternative treatments available for SHTG, such as dietary supplements and herbal remedies, which can compete with conventional treatments.
There is limited research on SHTG compared to other cardiovascular conditions, which can hinder the development of new treatments and diagnostic tools. Regulatory challenges such as delays in approval processes and changing regulatory requirements can increase the time and cost associated with developing and bringing new SHTG treatments to market.
Region-Wise Insights
Increasing Healthcare Expenditure Bolstering Demand for SHTG Treatment Market in North America?
High Prevalence of SHTG boosting growth of SHTG treatment market in North America
North America has a high prevalence of SHTG, which is expected to drive the growth of the market. North America is home to some of the leading pharmaceutical and medical device companies in the world, which have been instrumental in developing new drugs and medical devices for the treatment of SHTG.
North America has a well-developed healthcare system with advanced healthcare facilities, which enable early diagnosis and treatment of SHTG. Healthcare expenditure in North America is among the highest in the world, which is expected to drive the growth of the SHTG treatment market.
Governments in North America have taken several initiatives to promote awareness about SHTG and to provide better access to SHTG treatment, which is creating a favorable environment for the growth of the market. Thus, North America is expected to possess 45% market share for SHTG market in 2023.
Government initiatives in Europe Propelling Growth of SHTG Treatment Market?
Rising awareness of STHG increasing dependency on treatment for ailment in Europe
There has been a growing prevalence of SHTG in Europe due to changing lifestyle patterns, such as unhealthy diets and sedentary lifestyles, leading to an increase in the incidence of obesity, diabetes, and other related diseases. There have been significant advancements in the development of novel drugs and therapies for the treatment of SHTG, which are driving the growth of the market. These include newer lipid-lowering agents, such as omega-3 fatty acids, fibrates, and niacin.
There is a growing awareness among healthcare professionals and patients about the risks associated with SHTG, which has led to increased diagnosis rates and greater demand for effective treatment options. The government is taking initiatives to promote awareness and education about SHTG and its treatment options, which is likely to drive market growth. Additionally, healthcare policies aimed at improving access to healthcare services, particularly in rural areas, are also contributing to market growth.
With the increasing burden of SHTG, healthcare expenditure is expected to rise in the coming years, which will drive the growth of the SHTG treatment market in Europe. Thus, Europe is expected to possess 39% market share for SHTG treatment market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
Access to specialized medications making hospital pharmacies Popular for SHTG Treatment Market?
Availability of inpatient care making hospital pharmacies dependable for SHTG treatment market
Hospital pharmacies may have access to a wider range of medications that are not available in retail pharmacies. This may be especially important for the treatment of SHTG, as specialized medications such as omega-3 fatty acids and fibrates may be needed to effectively manage the condition.
Hospital pharmacists are often highly trained and have specialized knowledge in the treatment of complex medical conditions such as SHTG. They can work closely with physicians and other healthcare professionals to ensure that patients receive the most appropriate medications and dosages.
In cases where patients with SHTG require hospitalization, hospital pharmacies can provide medications and other treatments as part of a coordinated inpatient care plan. Hospital pharmacies can help monitor medication adherence, which is especially important for the treatment of chronic conditions such as SHTG. This can help ensure that patients receive the appropriate medications at the right time and in the correct dosages. Thus, hospital pharmacies are expected to possess 40% market share for SHTG treatment market in 2023.
Market Competition
Key players in the severe hypertriglyceridemia (SHTG) treatment market areIonis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., NorthSea Therapeutics B.V., Amryt Pharma, Afimmune Pharmaceutical, Zucara Therapeutics, Novo Nordisk, Adocia and Pfizer Inc.
Ionis Pharmaceuticals is a biotechnology company that specializes in the discovery and development of RNA-targeted therapies. The company has developed a drug called volanesorsen (brand name Waylivra), which is used in the treatment of Severe Hypertriglyceridemia (SHTG).
89bio, Inc. is a biopharmaceutical company that has been developing therapies for the treatment of severe hypertriglyceridemia (SHTG). The company's lead drug candidate, called BIO89-100, is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed as a potential treatment for SHTG. In preclinical studies, BIO89-100 has been shown to significantly reduce triglyceride levels in animal models of SHTG.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 702.95 Million
Market Value in 2033
US$ 2675.37 Million
Growth Rate
CAGR of 14.3% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
Drug Class
Drug Delivery Method
Distribution Channel
Region
Regions Covered
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Key Countries Profiled
USA
Canada
Brazil
Mexico
Rest of Latin America
Germany
United kingdom
France
Spain
Italy
Rest of Europe
India
Malaysia
Singapore
Thailand
Rest of South Asia
China
Japan
South Korea
Austria
New Zealand
GCC countries
South Africa
Israel
Rest of MEA
Key Companies Profiled
Ionis Pharmaceuticals
89bio, Inc.
Arrowhead Pharmaceuticals, Inc.
NorthSea Therapeutics B.V.
Amryt Pharma
Afimmune Pharmaceutical
Zucara Therapeutics
Novo Nordisk
Adocia
Pfizer Inc.
Customization
Available Upon Request
Key Segments Profiled in the Severe Hypertriglyceridemia (SHTG) Treatment Market Survey
Drug Class:
Olezarsen
Pegozafermin
Epeleuton
Lomitapide
Drug Delivery Method:
Oral Route
Injectable Route
Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Frequently Asked Questions
At what rate did the Severe hypertriglyceridemia (SHTG) treatment market flourish from 2018-2022?
From 2018-2022, the Severe hypertriglyceridemia (SHTG) treatment market grew at a CAGR of 8%
What will be the growth rate of the global Severe hypertriglyceridemia (SHTG) treatment market during the forecast period?
The global Severe hypertriglyceridemia (SHTG) treatment market is expected to grow with a 14.3% CAGR during 2023 to 2033.
What will be the projected market size of the Severe hypertriglyceridemia (SHTG) treatment market by 2033?
As of 2033, the Severe hypertriglyceridemia (SHTG) treatment market is expected to reach US$ 2675.37 Million
Which distribution channel segment is expected to dominate the global Severe hypertriglyceridemia (SHTG) treatment market during 2033?
Hospital pharmacies are expected to hold 40% of the market share in 2023 for Severe hypertriglyceridemia (SHTG) treatment market.
How is the North America Severe hypertriglyceridemia (SHTG) treatment market projected to grow in 2033?
North America is expected to possess 45% market share for Severe hypertriglyceridemia (SHTG) treatment market in 2023.
How is the Europe Severe hypertriglyceridemia (SHTG) treatment market projected to grow in 2033?
Europe severe hypertriglyceridemia (SHTG) treatment market size is expected to possess 39% market share in 2023.
Table of Content
1. Executive Summary | Severe Hypertriglyceridemia (SHTG) Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Olezarsen
5.3.2. Pegozafermin
5.3.3. Epeleuton
5.3.4. Lomitapide
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Delivery Method
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Drug Delivery Method, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Delivery Method, 2023 to 2033
6.3.1. Oral Route
6.3.2. Injectable Route
6.4. Y-o-Y Growth Trend Analysis By Drug Delivery Method, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Drug Delivery Method, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Drug Delivery Method
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Drug Delivery Method
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Drug Delivery Method
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Drug Delivery Method
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Drug Delivery Method
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Drug Delivery Method
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Drug Class
12.2.3. By Drug Delivery Method
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Drug Delivery Method
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug Class
13.2.3. By Drug Delivery Method
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Drug Delivery Method
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Drug Class
14.2.3. By Drug Delivery Method
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Drug Delivery Method
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Drug Class
15.2.3. By Drug Delivery Method
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Drug Delivery Method
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Drug Class
16.1.2.2. By Drug Delivery Method
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Drug Class
16.2.2.2. By Drug Delivery Method
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Drug Class
16.3.2.2. By Drug Delivery Method
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Drug Class
16.4.2.2. By Drug Delivery Method
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Drug Class
16.5.2.2. By Drug Delivery Method
16.5.2.3. By Distribution Channel
16.6. United kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Drug Class
16.6.2.2. By Drug Delivery Method
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Drug Class
16.7.2.2. By Drug Delivery Method
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Drug Class
16.8.2.2. By Drug Delivery Method
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Drug Class
16.9.2.2. By Drug Delivery Method
16.9.2.3. By Distribution Channel
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Drug Class
16.10.2.2. By Drug Delivery Method
16.10.2.3. By Distribution Channel
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Drug Class
16.11.2.2. By Drug Delivery Method
16.11.2.3. By Distribution Channel
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Drug Class
16.12.2.2. By Drug Delivery Method
16.12.2.3. By Distribution Channel
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Drug Class
16.13.2.2. By Drug Delivery Method
16.13.2.3. By Distribution Channel
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Drug Class
16.14.2.2. By Drug Delivery Method
16.14.2.3. By Distribution Channel
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Drug Class
16.15.2.2. By Drug Delivery Method
16.15.2.3. By Distribution Channel
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Drug Class
16.16.2.2. By Drug Delivery Method
16.16.2.3. By Distribution Channel
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Drug Class
16.17.2.2. By Drug Delivery Method
16.17.2.3. By Distribution Channel
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Drug Class
16.18.2.2. By Drug Delivery Method
16.18.2.3. By Distribution Channel
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Drug Class
16.19.2.2. By Drug Delivery Method
16.19.2.3. By Distribution Channel
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Drug Class
16.20.2.2. By Drug Delivery Method
16.20.2.3. By Distribution Channel
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Drug Class
16.21.2.2. By Drug Delivery Method
16.21.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Drug Class
17.3.3. By Drug Delivery Method
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Ionis Pharmaceuticals
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. 89bio, Inc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Arrowhead Pharmaceuticals, Inc.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. NorthSea Therapeutics B.V.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Amryt Pharma
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Afimmune Pharmaceutical
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Zucara Therapeutics
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Novo Nordisk
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Adocia
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Pfizer Inc.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Drug Delivery Method, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Drug Delivery Method, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Drug Delivery Method, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Drug Delivery Method, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 19: South Asia Market Value (US$ Million) Forecast by Drug Delivery Method, 2018 to 2033
Table 20: South Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 23: East Asia Market Value (US$ Million) Forecast by Drug Delivery Method, 2018 to 2033
Table 24: East Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 27: Oceania Market Value (US$ Million) Forecast by Drug Delivery Method, 2018 to 2033
Table 28: Oceania Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 31: MEA Market Value (US$ Million) Forecast by Drug Delivery Method, 2018 to 2033
Table 32: MEA Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Drug Delivery Method, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Drug Delivery Method, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Drug Delivery Method, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Drug Delivery Method, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 18: Global Market Attractiveness by Drug Delivery Method, 2023 to 2033
Figure 19: Global Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Drug Delivery Method, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Drug Delivery Method, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Drug Delivery Method, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Drug Delivery Method, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 38: North America Market Attractiveness by Drug Delivery Method, 2023 to 2033
Figure 39: North America Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Drug Delivery Method, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Drug Delivery Method, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Drug Delivery Method, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Drug Delivery Method, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Drug Delivery Method, 2023 to 2033
Figure 59: Latin America Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Drug Delivery Method, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Drug Delivery Method, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Drug Delivery Method, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Drug Delivery Method, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 77: Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 78: Europe Market Attractiveness by Drug Delivery Method, 2023 to 2033
Figure 79: Europe Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 82: South Asia Market Value (US$ Million) by Drug Delivery Method, 2023 to 2033
Figure 83: South Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 89: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 91: South Asia Market Value (US$ Million) Analysis by Drug Delivery Method, 2018 to 2033
Figure 92: South Asia Market Value Share (%) and BPS Analysis by Drug Delivery Method, 2023 to 2033
Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Drug Delivery Method, 2023 to 2033
Figure 94: South Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 95: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 97: South Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 98: South Asia Market Attractiveness by Drug Delivery Method, 2023 to 2033
Figure 99: South Asia Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 101: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 102: East Asia Market Value (US$ Million) by Drug Delivery Method, 2023 to 2033
Figure 103: East Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 109: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 111: East Asia Market Value (US$ Million) Analysis by Drug Delivery Method, 2018 to 2033
Figure 112: East Asia Market Value Share (%) and BPS Analysis by Drug Delivery Method, 2023 to 2033
Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Drug Delivery Method, 2023 to 2033
Figure 114: East Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 115: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 117: East Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 118: East Asia Market Attractiveness by Drug Delivery Method, 2023 to 2033
Figure 119: East Asia Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 121: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 122: Oceania Market Value (US$ Million) by Drug Delivery Method, 2023 to 2033
Figure 123: Oceania Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 131: Oceania Market Value (US$ Million) Analysis by Drug Delivery Method, 2018 to 2033
Figure 132: Oceania Market Value Share (%) and BPS Analysis by Drug Delivery Method, 2023 to 2033
Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Drug Delivery Method, 2023 to 2033
Figure 134: Oceania Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 137: Oceania Market Attractiveness by Drug Class, 2023 to 2033
Figure 138: Oceania Market Attractiveness by Drug Delivery Method, 2023 to 2033
Figure 139: Oceania Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 141: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 142: MEA Market Value (US$ Million) by Drug Delivery Method, 2023 to 2033
Figure 143: MEA Market Value (US$ Million) by Distribution Channel , 2023 to 2033
Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 151: MEA Market Value (US$ Million) Analysis by Drug Delivery Method, 2018 to 2033
Figure 152: MEA Market Value Share (%) and BPS Analysis by Drug Delivery Method, 2023 to 2033
Figure 153: MEA Market Y-o-Y Growth (%) Projections by Drug Delivery Method, 2023 to 2033
Figure 154: MEA Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033
Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033
Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033
Figure 157: MEA Market Attractiveness by Drug Class, 2023 to 2033
Figure 158: MEA Market Attractiveness by Drug Delivery Method, 2023 to 2033
Figure 159: MEA Market Attractiveness by Distribution Channel , 2023 to 2033
Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
